PANACEABIOBSEPanacea Biotec LtdMediumNeutral
Announced Fri, 29 May · 16:34 IST

We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, ....

Management Changes View source PDF

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.4%1-day move
₹411.00
prior close
₹402.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.8+3.8+3.6+9.4+4.4+5.6+26.6+33.8+34.5+33.1+27.6+32.1
Up moveDown movePending
AI summary

Panacea Biotec's wholly owned subsidiary Panacea Biotec Pharma Ltd (PBPL) has approved two board changes. Mr. Krishan Kumar Jalan, a retired IAS officer with over 35 years of administrative experience, has been appointed as an additional non-executive independent director from July 1, 2026, until February 13, 2030. Mrs. Manjula Upadhyay, a practicing lawyer with 37 years of experience in labour laws, has been re-appointed for a fresh 5-year term from July 23, 2026, to July 22, 2031. Both appointments are subject to shareholder approval. Neither director is related to any existing board members.

Likely market impact

The subsidiary's board is being reinforced with experienced independent directors bringing governance and legal expertise, which is positive for corporate oversight without any immediate shareholder value impact.